



Бекітешін:  
ТОО «Children's Castle»  
бапызбаптысынан мемлекеттік мектебі  
м.ә. Гүрлұханбетова

«Еркемші» ерсек тоғызының

2023- 2024 оқу жылына арналған

Ұйымдастырылған іс-әрекеттің ізгерлеушелі

Тәжірибелік психологияның

Papercraft - Ultra Geely Papercraft Ultra Papercraft

Kenny Jones et al. 2021 *Environ Biol Fish*







Key Information		Key Information		Key Information		Key Information		Key Information		Key Information	
Category	Description	Category	Description	Category	Description	Category	Description	Category	Description	Category	Description
Business Entity	ABC Corp.	Business Entity	XYZ Inc.	Business Entity	DEF Ltd.	Business Entity	GHI Corp.	Business Entity	JKL Corp.	Business Entity	MNO Corp.
Address	123 Main St, Anytown, USA	Address	456 Elm St, Anytown, USA	Address	789 Oak St, Anytown, USA	Address	101 Pine St, Anytown, USA	Address	202 Cedar St, Anytown, USA	Address	303 Birch St, Anytown, USA
Phone Number	(555) 123-4567	Phone Number	(555) 234-5678	Phone Number	(555) 345-6789	Phone Number	(555) 456-7890	Phone Number	(555) 567-8901	Phone Number	(555) 678-9012
Email Address	info@abc.com	Email Address	info@xyz.com	Email Address	info@def.com	Email Address	info@ghi.com	Email Address	info@jkl.com	Email Address	info@mno.com
Website URL	www.abc.com	Website URL	www.xyz.com	Website URL	www.def.com	Website URL	www.ghi.com	Website URL	www.jkl.com	Website URL	www.mno.com
Business Type	Manufacturing	Business Type	Retail	Business Type	Services	Business Type	Manufacturing	Business Type	Services	Business Type	Retail
Industry Sector	Automotive	Industry Sector	Consumer Goods	Industry Sector	Healthcare	Industry Sector	Automotive	Industry Sector	Healthcare	Industry Sector	Consumer Goods
Revenue Range	\$10M - \$50M	Revenue Range	\$50M - \$100M	Revenue Range	\$100M - \$200M	Revenue Range	\$10M - \$50M	Revenue Range	\$50M - \$100M	Revenue Range	\$100M - \$200M
Profit Margin	10%	Profit Margin	15%	Profit Margin	20%	Profit Margin	10%	Profit Margin	15%	Profit Margin	20%
Number of Employees	100	Number of Employees	200	Number of Employees	300	Number of Employees	100	Number of Employees	200	Number of Employees	300
Headquarters Location	New York City, NY	Headquarters Location	Los Angeles, CA	Headquarters Location	Chicago, IL	Headquarters Location	New York City, NY	Headquarters Location	Los Angeles, CA	Headquarters Location	Chicago, IL
Primary Product/Service	Car Parts	Primary Product/Service	Electronics	Primary Product/Service	Pharmaceuticals	Primary Product/Service	Car Parts	Primary Product/Service	Electronics	Primary Product/Service	Pharmaceuticals
Market Segment	Automotive OEMs	Market Segment	Consumer Electronics	Market Segment	Healthcare Providers	Market Segment	Automotive OEMs	Market Segment	Consumer Electronics	Market Segment	Healthcare Providers
Competitor Analysis	BMW, Toyota, GM	Competitor Analysis	Samsung, Apple, LG	Competitor Analysis	Pfizer, Novartis, Gilead	Competitor Analysis	BMW, Toyota, GM	Competitor Analysis	Samsung, Apple, LG	Competitor Analysis	Pfizer, Novartis, Gilead
Market Share (%)	5%	Market Share (%)	10%	Market Share (%)	15%	Market Share (%)	5%	Market Share (%)	10%	Market Share (%)	15%
Market Growth Rate	2% CAGR	Market Growth Rate	3% CAGR	Market Growth Rate	4% CAGR	Market Growth Rate	2% CAGR	Market Growth Rate	3% CAGR	Market Growth Rate	4% CAGR
Risk Exposure	Medium	Risk Exposure	Low	Risk Exposure	High	Risk Exposure	Medium	Risk Exposure	Low	Risk Exposure	High
Regulatory Environment	Stable	Regulatory Environment	Challenging	Regulatory Environment	Complex	Regulatory Environment	Stable	Regulatory Environment	Challenging	Regulatory Environment	Complex
Geographic Focus	North America	Geographic Focus	Asia Pacific	Geographic Focus	Europe	Geographic Focus	North America	Geographic Focus	Asia Pacific	Geographic Focus	Europe
Supply Chain Complexity	Simple	Supply Chain Complexity	Medium	Supply Chain Complexity	Complex	Supply Chain Complexity	Simple	Supply Chain Complexity	Medium	Supply Chain Complexity	Complex
Customer Acquisition Cost	\$100	Customer Acquisition Cost	\$200	Customer Acquisition Cost	\$300	Customer Acquisition Cost	\$100	Customer Acquisition Cost	\$200	Customer Acquisition Cost	\$300
Customer Retention Rate	85%	Customer Retention Rate	90%	Customer Retention Rate	95%	Customer Retention Rate	85%	Customer Retention Rate	90%	Customer Retention Rate	95%
Customer Satisfaction Score	4.2	Customer Satisfaction Score	4.5	Customer Satisfaction Score	4.8	Customer Satisfaction Score	4.2	Customer Satisfaction Score	4.5	Customer Satisfaction Score	4.8
Product Line	Engines, Brakes, Batteries	Product Line	Smartphones, Tablets, Laptops	Product Line	Drugs, Devices, Diagnostics	Product Line	Engines, Brakes, Batteries	Product Line	Smartphones, Tablets, Laptops	Product Line	Drugs, Devices, Diagnostics
Product Line Description	Automotive components produced by ABC Corp.	Product Line Description	Consumer electronics produced by XYZ Inc.	Product Line Description	Pharmaceuticals produced by DEF Ltd.	Product Line Description	Automotive components produced by ABC Corp.	Product Line Description	Consumer electronics produced by XYZ Inc.	Product Line Description	Pharmaceuticals produced by DEF Ltd.
Product Line Features	High performance, long-lasting, reliable	Product Line Features	Fast processing, high-resolution, durable	Product Line Features	Effective treatments, safe, well-tolerated	Product Line Features	High performance, long-lasting, reliable	Product Line Features	Fast processing, high-resolution, durable	Product Line Features	Effective treatments, safe, well-tolerated
Product Line Benefits	Cost-effective, efficient, sustainable	Product Line Benefits	Innovative, user-friendly, accessible	Product Line Benefits	Advanced, targeted, effective	Product Line Benefits	Cost-effective, efficient, sustainable	Product Line Benefits	Innovative, user-friendly, accessible	Product Line Benefits	Advanced, targeted, effective
Product Line Challenges	Supply chain issues, regulatory hurdles	Product Line Challenges	Competition, market saturation	Product Line Challenges	Side effects, cost	Product Line Challenges	Supply chain issues, regulatory hurdles	Product Line Challenges	Competition, market saturation	Product Line Challenges	Side effects, cost
Product Line Opportunities	Global expansion, new technologies	Product Line Opportunities	Emerging markets, AI integration	Product Line Opportunities	Personalized medicine, partnerships	Product Line Opportunities	Global expansion, new technologies	Product Line Opportunities	Emerging markets, AI integration	Product Line Opportunities	Personalized medicine, partnerships
Product Line Risks	Regulatory changes, economic fluctuations	Product Line Risks	Technological advancements, geopolitical risks	Product Line Risks	Side effects, cost	Product Line Risks	Regulatory changes, economic fluctuations	Product Line Risks	Technological advancements, geopolitical risks	Product Line Risks	Side effects, cost
Product Line Outlook	Positive, strong growth expected	Product Line Outlook	Neutral, market dynamics mixed	Product Line Outlook	Negative, challenges ahead	Product Line Outlook	Positive, strong growth expected	Product Line Outlook	Neutral, market dynamics mixed	Product Line Outlook	Negative, challenges ahead
Product Line Status	Stable, no significant changes	Product Line Status	Stable, no significant changes	Product Line Status	Stable, no significant changes	Product Line Status	Stable, no significant changes	Product Line Status	Stable, no significant changes	Product Line Status	Stable, no significant changes
Product Line Performance	Good, meeting targets	Product Line Performance	Good, meeting targets	Product Line Performance	Good, meeting targets	Product Line Performance	Good, meeting targets	Product Line Performance	Good, meeting targets	Product Line Performance	Good, meeting targets
Product Line Impact	Significant, positive impact	Product Line Impact	Significant, positive impact	Product Line Impact	Significant, positive impact	Product Line Impact	Significant, positive impact	Product Line Impact	Significant, positive impact	Product Line Impact	Significant, positive impact
Product Line Risk	Medium, manageable	Product Line Risk	Medium, manageable	Product Line Risk	Medium, manageable	Product Line Risk	Medium, manageable	Product Line Risk	Medium, manageable	Product Line Risk	Medium, manageable
Product Line Opportunity	High, significant opportunities	Product Line Opportunity	High, significant opportunities	Product Line Opportunity	High, significant opportunities	Product Line Opportunity	High, significant opportunities	Product Line Opportunity	High, significant opportunities	Product Line Opportunity	High, significant opportunities
Product Line Threat	Medium, potential threats	Product Line Threat	Medium, potential threats	Product Line Threat	Medium, potential threats	Product Line Threat	Medium, potential threats	Product Line Threat	Medium, potential threats	Product Line Threat	Medium, potential threats
Product Line Strategy	Focus on innovation, cost reduction	Product Line Strategy	Focus on innovation, cost reduction	Product Line Strategy	Focus on innovation, cost reduction	Product Line Strategy	Focus on innovation, cost reduction	Product Line Strategy	Focus on innovation, cost reduction	Product Line Strategy	Focus on innovation, cost reduction
Product Line Conclusion	Overall positive, strong growth expected	Product Line Conclusion	Overall positive, strong growth expected	Product Line Conclusion	Overall positive, strong growth expected	Product Line Conclusion	Overall positive, strong growth expected	Product Line Conclusion	Overall positive, strong growth expected	Product Line Conclusion	Overall positive, strong growth expected
Product Line Summary	ABC Corp. is positioned well for future growth across all product lines, driven by strong market demand and effective operational management.	XYZ Inc. is maintaining its market share but faces increasing competition from established players.	DEF Ltd. is experiencing challenges due to regulatory hurdles and side effects, but has potential through partnerships and new technologies.	ABC Corp. is positioned well for future growth across all product lines, driven by strong market demand and effective operational management.	XYZ Inc. is maintaining its market share but faces increasing competition from established players.	DEF Ltd. is experiencing challenges due to regulatory hurdles and side effects, but has potential through partnerships and new technologies.	ABC Corp. is positioned well for future growth across all product lines, driven by strong market demand and effective operational management.	XYZ Inc. is maintaining its market share but faces increasing competition from established players.	DEF Ltd. is experiencing challenges due to regulatory hurdles and side effects, but has potential through partnerships and new technologies.	ABC Corp. is positioned well for future growth across all product lines, driven by strong market demand and effective operational management.	XYZ Inc. is maintaining its market share but faces increasing competition from established players.





Температура - это мера интенсивности тепловой энергии.

THE HIGHWAYMAN

Business Unit		Period		Revenue		Profit		EBITDA		Net Income		EPS	
Category	Sub-Category	Start Date	End Date	Gross Revenue	Net Revenue	Gross Profit	Net Profit	Gross EBITDA	Net EBITDA	Gross Net Income	Net Net Income	EPS (Basic)	EPS (Diluted)
Business Unit A	Product Line A	2023-01-01	2023-06-30	120,000	110,000	30,000	25,000	45,000	40,000	15,000	12,000	0.10	0.10
Business Unit B	Product Line B	2023-02-01	2023-07-31	130,000	120,000	35,000	30,000	50,000	45,000	18,000	15,000	0.12	0.12
Business Unit C	Product Line C	2023-03-01	2023-08-31	140,000	130,000	40,000	35,000	55,000	50,000	20,000	18,000	0.14	0.14
Business Unit D	Product Line D	2023-04-01	2023-09-30	150,000	140,000	45,000	40,000	60,000	55,000	22,000	20,000	0.16	0.16
Business Unit E	Product Line E	2023-05-01	2023-10-31	160,000	150,000	50,000	45,000	65,000	60,000	25,000	22,000	0.18	0.18
Business Unit F	Product Line F	2023-06-01	2023-11-30	170,000	160,000	55,000	50,000	70,000	65,000	28,000	25,000	0.20	0.20
Business Unit G	Product Line G	2023-07-01	2023-12-31	180,000	170,000	60,000	55,000	75,000	70,000	30,000	28,000	0.22	0.22
Business Unit H	Product Line H	2023-08-01	2024-01-31	190,000	180,000	65,000	60,000	80,000	75,000	32,000	30,000	0.24	0.24
Business Unit I	Product Line I	2023-09-01	2024-02-28	200,000	190,000	70,000	65,000	85,000	80,000	35,000	32,000	0.26	0.26
Business Unit J	Product Line J	2023-10-01	2024-03-31	210,000	200,000	75,000	70,000	90,000	85,000	38,000	35,000	0.28	0.28
Business Unit K	Product Line K	2023-11-01	2024-04-30	220,000	210,000	80,000	75,000	95,000	90,000	40,000	38,000	0.30	0.30
Business Unit L	Product Line L	2023-12-01	2024-05-31	230,000	220,000	85,000	80,000	100,000	95,000	42,000	40,000	0.32	0.32
Business Unit M	Product Line M	2024-01-01	2024-06-30	240,000	230,000	90,000	85,000	105,000	100,000	45,000	42,000	0.34	0.34
Business Unit N	Product Line N	2024-02-01	2024-07-31	250,000	240,000	95,000	90,000	110,000	105,000	48,000	45,000	0.36	0.36
Business Unit O	Product Line O	2024-03-01	2024-08-31	260,000	250,000	100,000	95,000	115,000	110,000	50,000	48,000	0.38	0.38
Business Unit P	Product Line P	2024-04-01	2024-09-30	270,000	260,000	105,000	100,000	120,000	115,000	52,000	50,000	0.40	0.40
Business Unit Q	Product Line Q	2024-05-01	2024-10-31	280,000	270,000	110,000	105,000	125,000	120,000	55,000	52,000	0.42	0.42
Business Unit R	Product Line R	2024-06-01	2024-11-30	290,000	280,000	115,000	110,000	130,000	125,000	58,000	55,000	0.44	0.44
Business Unit S	Product Line S	2024-07-01	2025-01-31	300,000	290,000	120,000	115,000	135,000	130,000	60,000	58,000	0.46	0.46
Business Unit T	Product Line T	2024-08-01	2025-02-28	310,000	300,000	125,000	120,000	140,000	135,000	62,000	60,000	0.48	0.48
Business Unit U	Product Line U	2024-09-01	2025-03-31	320,000	310,000	130,000	125,000	145,000	140,000	65,000	62,000	0.50	0.50
Business Unit V	Product Line V	2024-10-01	2025-04-30	330,000	320,000	135,000	130,000	150,000	145,000	68,000	65,000	0.52	0.52
Business Unit W	Product Line W	2024-11-01	2025-05-31	340,000	330,000	140,000	135,000	155,000	150,000	70,000	68,000	0.54	0.54
Business Unit X	Product Line X	2024-12-01	2025-06-30	350,000	340,000	145,000	140,000	160,000	155,000	72,000	70,000	0.56	0.56
Business Unit Y	Product Line Y	2025-01-01	2025-07-31	360,000	350,000	150,000	145,000	165,000	160,000	75,000	72,000	0.58	0.58
Business Unit Z	Product Line Z	2025-02-01	2025-08-31	370,000	360,000	155,000	150,000	170,000	165,000	78,000	75,000	0.60	0.60
Business Unit AA	Product Line AA	2025-03-01	2025-09-30	380,000	370,000	160,000	155,000	175,000	170,000	80,000	78,000	0.62	0.62
Business Unit BB	Product Line BB	2025-04-01	2025-10-31	390,000	380,000	165,000	160,000	180,000	175,000	82,000	80,000	0.64	0.64
Business Unit CC	Product Line CC	2025-05-01	2025-11-30	400,000	390,000	170,000	165,000	185,000	180,000	85,000	82,000	0.66	0.66
Business Unit DD	Product Line DD	2025-06-01	2025-12-31	410,000	400,000	175,000	170,000	190,000	185,000	88,000	85,000	0.68	0.68
Business Unit EE	Product Line EE	2025-07-01	2026-01-31	420,000	410,000	180,000	175,000	195,000	190,000	90,000	88,000	0.70	0.70
Business Unit FF	Product Line FF	2025-08-01	2026-02-28	430,000	420,000	185,000	180,000	200,000	195,000	92,000	90,000	0.72	0.72
Business Unit GG	Product Line GG	2025-09-01	2026-03-31	440,000	430,000	190,000	185,000	205,000	200,000	95,000	92,000	0.74	0.74
Business Unit HH	Product Line HH	2025-10-01	2026-04-30	450,000	440,000	195,000	190,000	210,000	205,000	98,000	95,000	0.76	0.76
Business Unit II	Product Line II	2025-11-01	2026-05-31	460,000	450,000	200,000	195,000	215,000	210,000	100,000	98,000	0.78	0.78
Business Unit JJ	Product Line JJ	2025-12-01	2026-06-30	470,000	460,000	205,000	200,000	220,000	215,000	102,000	100,000	0.80	0.80
Business Unit KK	Product Line KK	2026-01-01	2026-07-31	480,000	470,000	210,000	205,000	225,000	220,000	105,000	102,000	0.82	0.82
Business Unit LL	Product Line LL	2026-02-01	2026-08-31	490,000	480,000	215,000	210,000	230,000	225,000	108,000	105,000	0.84	0.84
Business Unit MM	Product Line MM	2026-03-01	2026-09-30	500,000	490,000	220,000	215,000	235,000	230,000	110,000	108,000	0.86	0.86
Business Unit NN	Product Line NN	2026-04-01	2026-10-31	510,000	500,000	225,000	220,000	240,000	235,000	112,000	110,000	0.88	0.88
Business Unit OO	Product Line OO	2026-05-01	2026-11-30	520,000	510,000	230,000	225,000	245,000	240,000	115,000	112,000	0.90	0.90
Business Unit PP	Product Line PP	2026-06-01	2027-01-31	530,000	520,000	235,000	230,000	250,000	245,000	118,000	115,000	0.92	0.92
Business Unit QQ	Product Line QQ	2026-07-01	2027-02-28	540,000	530,000	240,000	235,000	255,000	250,000	120,000	118,000	0.94	0.94
Business Unit RR	Product Line RR	2026-08-01	2027-03-31	550,000	540,000	245,000	240,000	260,000	255,000	122,000	120,000	0.96	0.96
Business Unit SS	Product Line SS	2026-09-01	2027-04-30	560,000	550,000	250,000	245,000	265,000	260,000	125,000	122,000	0.98	0.98
Business Unit TT	Product Line TT	2026-10-01	2027-05-31	570,000	560,000	255,000	250,000	270,000	265,000	128,000	125,000	1.00	1.00
Business Unit UU	Product Line UU	2026-11-01	2027-06-30	580,000	570,000	260,000	255,000	275,000	270,000	130,000	128,000	1.02	1.02
Business Unit VV	Product Line VV	2026-12-01	2027-07-31	590,000	580,000	265,000	260,000	280,000	275,000	132,000	130,000	1.04	1.04
Business Unit WW	Product Line WW	2027-01-01	2027-08-31	600,000	590,000	270,000	265,000	285,000	280,000	135,000	132,000	1.06	1.06
Business Unit XX	Product Line XX	2027-02-01	2027-09-30	610,000	600,000	275,000	270,000	290,000	285,000	138,000	135,000	1.08	1.08
Business Unit YY	Product Line YY	2027-03-01	2027-10-31	620,000	610,000	280,000	275,000	295,000	290,000	140,000	138,000	1.10	1.10
Business Unit ZZ	Product Line ZZ	2027-04-01	2027-11-30	630,000	620,000	285,000	280,000	300,000	295,000	142,000	140,000	1.12	1.12
Business Unit AA	Product Line AA	2027-05-01	2028-01-31	640,000	630,000	290,000	285,000	305,000	290,000	145,000	142,000	1.14	1.14
Business Unit BB	Product Line BB	2027-06-01	2028-02-28	650,000	640,000	295,000	290,000	310,000	295,000	148,000	145,000	1.16	1.16
Business Unit CC	Product Line CC	2027-07-01	2028-03-31	660,000	650,000	300,000	295,000	315,000	290,000	150,000	148,000	1.18	1.18
Business Unit DD	Product Line DD	2027-08-01	2028-04-30	670,000	660,000	305,000	300,000	320,000	285,000	152,000	150,000	1.20	1.20
Business Unit EE	Product Line EE	2027-09-01	2028-05-31	680,000	670,000	310,000	305,000	325,000	280,000	155,000	152,000	1.22	1.22
Business Unit FF	Product Line FF	2027-10-01	2028-06-30	690,000	680,000	315,000	310,000	330,000	275,000	158,000	155,000	1.24	1.24
Business Unit GG	Product Line GG	2027-11-01	2028-07-31	700,000	690,000	320,000	315,000	335,000	270,000	160,000	158,000	1.26	1.26
Business Unit HH	Product Line HH	2027-12-01	2028-08-31	710,000	700,000	325,000	320,000	340,000	265,000	162,000	160,000	1.28	1.28
Business Unit II	Product Line II	2028-01-01	2029-01-31	720,000	710,000	330,000	325,000	345,000	260,000	165,000	162,000	1.30	1.30
Business Unit III	Product Line III	2028-02-01	2029-02-28	730,000	720,000	335,000	330,000	350,000	255,000	168,000	165,000	1.32	1.32
Business Unit IV	Product Line IV	2028-03-01	2029-03-31	740,000	730,000	340,000	335,000	355,000	250,000	170,000	168,000	1.34	1.34
Business Unit V	Product Line V	2028-04-01	2029-04-30	750,000	740,000	345,000	340,000	360,000	245,000	172,000	170,000	1.36	1.36
Business Unit VI	Product Line VI	2028-05-01	2029-05-31	760,000	750,000	350,000	345,000	365,000	240,000	175,000	172,000	1.38	1.38
Business Unit VII	Product Line VII	2028-06-01	2029-06-30	770,000	760,000	355,000	350,000	370,000	235,000	178,000	175,000	1.40	1.40
Business Unit VIII	Product Line VIII	2028-07-01	2029-07-31	780,000	770,000	360,000	355,000	375,000	230,000	180,000	178,000	1.42	1.42
Business Unit IX	Product Line IX	2028-08-01	2029-08-31	790,000	780,000	365,000	360,000	380,000	225,000	182,000	180,000	1.44	1.44
Business Unit X	Product Line X	2028-09-01	2029-09-30	800,000	790,000	370,000	365,000	385,000	220,000	185,000	182,000	1.46	1.46
Business Unit XI	Product Line XI	2028-10-01	2029-10-31	810,000	800,000	375,000	370,000	390,000	215,000	188,000	185,000	1.48	1.48
Business Unit XII	Product Line XII	2028-11-01	2029-11-30	820,000	810,000	380,000	375,000	395,000	210,000	190,000	188,000	1.50	1.50
Business Unit XIII	Product Line XIII	2028-12-01	2029-12-31	830,000	820,000	385,000	380,000	400,000	205,000	192,000	190,000	1.52	





Балтимор және АҚШ	Серуенге амниятшык	Кітапханалардың көмекшілігінде үйретілген мәдениет Кітапханалардың көмекшілігінде үйретілген мәдениет Серуенге амниятшык
		Коопоративтердің мемлекеттік мәдениеттегі рөлін анықтауда Коопоративтердің мемлекеттік мәдениеттегі рөлін анықтауда Серуенге амниятшык
		Ана-амниятшык Балтимор және АҚШ

Тарбиеу - білуң беру тәрсілелін шиктөрмей

NATION WITH 2025 EDITION | 11



• <b>Level 1:</b> <i>Initial Assessment</i>	• <b>Level 2:</b> <i>Refined Assessment</i>	• <b>Level 3:</b> <i>Final Assessment</i>	• <b>Level 4:</b> <i>Final Diagnosis</i>
• <b>Initial Assessment:</b> <i>Initial Assessment</i> is the first step in the process of diagnosis. It involves a detailed history taking and a physical examination. The history includes information about the patient's symptoms, their onset, duration, and progression. The physical examination includes a general survey of the patient's body, focusing on areas where symptoms are present. This stage also involves laboratory tests and imaging studies to rule out other conditions.	• <b>Refined Assessment:</b> <i>Refined Assessment</i> follows the initial assessment. It involves a more detailed evaluation of the patient's symptoms and signs. This may include further laboratory tests, imaging studies, or specialized tests. The goal is to narrow down the differential diagnosis and identify specific findings that support a particular diagnosis.	• <b>Final Assessment:</b> <i>Final Assessment</i> is the final stage of the diagnostic process. It involves a comprehensive evaluation of all available information, including the patient's history, physical examination, laboratory results, and imaging studies. The goal is to reach a definitive diagnosis and develop a treatment plan.	• <b>Final Diagnosis:</b> <i>Final Diagnosis</i> is the final stage of the diagnostic process. It involves a comprehensive evaluation of all available information, including the patient's history, physical examination, laboratory results, and imaging studies. The goal is to reach a definitive diagnosis and develop a treatment plan.
• <b>Initial Assessment:</b> <i>Initial Assessment</i> is the first step in the process of diagnosis. It involves a detailed history taking and a physical examination. The history includes information about the patient's symptoms, their onset, duration, and progression. The physical examination includes a general survey of the patient's body, focusing on areas where symptoms are present. This stage also involves laboratory tests and imaging studies to rule out other conditions.	• <b>Refined Assessment:</b> <i>Refined Assessment</i> follows the initial assessment. It involves a more detailed evaluation of the patient's symptoms and signs. This may include further laboratory tests, imaging studies, or specialized tests. The goal is to narrow down the differential diagnosis and identify specific findings that support a particular diagnosis.	• <b>Final Assessment:</b> <i>Final Assessment</i> is the final stage of the diagnostic process. It involves a comprehensive evaluation of all available information, including the patient's history, physical examination, laboratory results, and imaging studies. The goal is to reach a definitive diagnosis and develop a treatment plan.	• <b>Final Diagnosis:</b> <i>Final Diagnosis</i> is the final stage of the diagnostic process. It involves a comprehensive evaluation of all available information, including the patient's history, physical examination, laboratory results, and imaging studies. The goal is to reach a definitive diagnosis and develop a treatment plan.
• <b>Initial Assessment:</b> <i>Initial Assessment</i> is the first step in the process of diagnosis. It involves a detailed history taking and a physical examination. The history includes information about the patient's symptoms, their onset, duration, and progression. The physical examination includes a general survey of the patient's body, focusing on areas where symptoms are present. This stage also involves laboratory tests and imaging studies to rule out other conditions.	• <b>Refined Assessment:</b> <i>Refined Assessment</i> follows the initial assessment. It involves a more detailed evaluation of the patient's symptoms and signs. This may include further laboratory tests, imaging studies, or specialized tests. The goal is to narrow down the differential diagnosis and identify specific findings that support a particular diagnosis.	• <b>Final Assessment:</b> <i>Final Assessment</i> is the final stage of the diagnostic process. It involves a comprehensive evaluation of all available information, including the patient's history, physical examination, laboratory results, and imaging studies. The goal is to reach a definitive diagnosis and develop a treatment plan.	• <b>Final Diagnosis:</b> <i>Final Diagnosis</i> is the final stage of the diagnostic process. It involves a comprehensive evaluation of all available information, including the patient's history, physical examination, laboratory results, and imaging studies. The goal is to reach a definitive diagnosis and develop a treatment plan.



<p><i>Cyperus rotundus</i></p> <p>Киперній пальчатокореневий Ботанічний музей Ботанічний сад УжНУ Спільнота Cypri Species at VENUE:</p> <p>Україна, Волинь.</p>	<p>Киперній пальчатокореневий Ботанічний музей</p>	<p>Киперній пальчатокореневий Ботанічний музей Україна, Волинь.</p>
<p><i>Cyperus esculentus</i></p> <p>Киперній пальчатокореневий Ботанічний музей-заповідник (ЕПІ) Україна, Волинь.</p>	<p>Киперній пальчатокореневий Ботанічний музей-заповідник (ЕПІ)</p>	<p>Киперній пальчатокореневий Ботанічний музей-заповідник (ЕПІ)</p>
<p><i>Cyperus esculentus</i></p> <p>Киперній пальчатокореневий Ботанічний музей-заповідник (ЕПІ)</p>	<p>Киперній пальчатокореневий Ботанічний музей-заповідник (ЕПІ)</p>	<p>Киперній пальчатокореневий Ботанічний музей-заповідник (ЕПІ)</p>
<p><i>Cyperus rotundus</i></p> <p>Киперній пальчатокореневий Ботанічний музей-заповідник (ЕПІ)</p>	<p>Киперній пальчатокореневий Ботанічний музей-заповідник (ЕПІ)</p>	<p>Киперній пальчатокореневий Ботанічний музей-заповідник (ЕПІ)</p>

Тарбиеј - білім беру процесінің инженерлік мағынасы

LICENCIATURA EN DISEÑO 2021-2 DIA

Nome	Definizione	Caratteristiche	Procedura
Analisi dei dati	Analisi dei dati è il processo di analisi e interpretazione dei dati raccolti per scopi specifici.	Analisi dei dati comprende la raccolta, la pulizia, la preparazione, l'analisi e la visualizzazione dei dati per scopi specifici.	Analisi dei dati può essere eseguita manualmente o con l'utilizzo di strumenti software.
Visualizzazione dei dati	Visualizzazione dei dati è il processo di rappresentazione grafica dei dati raccolti per scopi specifici.	Visualizzazione dei dati comprende la creazione di grafici, diagrammi, mappe e altri strumenti visivi per rappresentare i dati in modo più intuitivo e comprensibile.	Visualizzazione dei dati può essere eseguita manualmente o con l'utilizzo di strumenti software.
Preparazione dei dati	Preparazione dei dati è il processo di pulizia e organizzazione dei dati raccolti per scopi specifici.	Preparazione dei dati comprende la rimozione di dati errati, la sostituzione di valori mancanti, la standardizzazione di valori e la creazione di nuovi campioni.	Preparazione dei dati può essere eseguita manualmente o con l'utilizzo di strumenti software.
Raccolta dei dati	Raccolta dei dati è il processo di raccolta di dati da fonti esterne per scopi specifici.	Raccolta dei dati comprende la definizione delle fonti da cui i dati vengono raccolti, la creazione di strumenti per la raccolta dei dati e la gestione della raccolta.	Raccolta dei dati può essere eseguita manualmente o con l'utilizzo di strumenti software.
Analisi qualitativa	Analisi qualitativa è un tipo di analisi che si concentra sulla qualità dei dati raccolti per scopi specifici.	Analisi qualitativa comprende la lettura e l'interpretazione dei dati raccolti per scopi specifici.	Analisi qualitativa può essere eseguita manualmente o con l'utilizzo di strumenti software.
Analisi quantitativa	Analisi quantitativa è un tipo di analisi che si concentra sulla quantità dei dati raccolti per scopi specifici.	Analisi quantitativa comprende la quantificazione dei dati raccolti per scopi specifici.	Analisi quantitativa può essere eseguita manualmente o con l'utilizzo di strumenti software.
Analisi strutturata	Analisi strutturata è un tipo di analisi che si concentra sulla struttura dei dati raccolti per scopi specifici.	Analisi strutturata comprende la analisi della struttura dei dati raccolti per scopi specifici.	Analisi strutturata può essere eseguita manualmente o con l'utilizzo di strumenti software.
Analisi non strutturata	Analisi non strutturata è un tipo di analisi che si concentra sulla natura non strutturata dei dati raccolti per scopi specifici.	Analisi non strutturata comprende la analisi della natura non strutturata dei dati raccolti per scopi specifici.	Analisi non strutturata può essere eseguita manualmente o con l'utilizzo di strumenti software.

